ES2125285T3 - Derivados inhibidores de la reabsorcion de adenosina de difenil-oxazoles, tiazoles e imidazoles. - Google Patents

Derivados inhibidores de la reabsorcion de adenosina de difenil-oxazoles, tiazoles e imidazoles.

Info

Publication number
ES2125285T3
ES2125285T3 ES93111910T ES93111910T ES2125285T3 ES 2125285 T3 ES2125285 T3 ES 2125285T3 ES 93111910 T ES93111910 T ES 93111910T ES 93111910 T ES93111910 T ES 93111910T ES 2125285 T3 ES2125285 T3 ES 2125285T3
Authority
ES
Spain
Prior art keywords
adenosine
imidazoles
tiazoles
difenil
oxazoles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93111910T
Other languages
English (en)
Inventor
Balasubramanian Neelakantan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2125285T3 publication Critical patent/ES2125285T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)

Abstract

SE PRESENTAN UNA SERIE DE DERIVADOS DEL 1-PIPERACINIL-NFENILACETAMIDO DE IMIDAZOLAS, TRIAZOLAS O OXAZOLAS DE 4,5-DIFENIL QUE SON NUEVOS INHIBIDORES DEL TRANSPORTE DE LA ADENOSINA Y QUE SE HA ENCONTRADO QUE SUMINISTRAN UNA PROTECCION ANTIISQUEMICA EFECTIVA PARA LOS TEJIDOS CNS, PARTICULARMENTE LAS NEURONAS. ASIMISMO SE PRESENTA UN METODO DE TRATAMIENTO PARA LA PROTECCION CONTRA LA ISQUEMIA CNS, TAL COMO LA RESULTANTE DE UN TRAUMA, GOLPE U OTRA CONDICION ISQUEMICA, EL METODO COMPRENDE LA ADMINISTRACION DE ESTOS NUEVOS COMPUESTOS A UN INDIVIDUO QUE NECESITE DE DICHO TRATAMIENTO.
ES93111910T 1992-07-31 1993-07-26 Derivados inhibidores de la reabsorcion de adenosina de difenil-oxazoles, tiazoles e imidazoles. Expired - Lifetime ES2125285T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92339992A 1992-07-31 1992-07-31
US4833893A 1993-04-15 1993-04-15

Publications (1)

Publication Number Publication Date
ES2125285T3 true ES2125285T3 (es) 1999-03-01

Family

ID=26726027

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93111910T Expired - Lifetime ES2125285T3 (es) 1992-07-31 1993-07-26 Derivados inhibidores de la reabsorcion de adenosina de difenil-oxazoles, tiazoles e imidazoles.

Country Status (19)

Country Link
US (1) US5382584A (es)
EP (1) EP0582164B1 (es)
JP (1) JP3478852B2 (es)
KR (1) KR940005614A (es)
CN (1) CN1085216A (es)
AT (1) ATE174913T1 (es)
AU (1) AU670953B2 (es)
CA (1) CA2101311A1 (es)
DE (1) DE69322707T2 (es)
DK (1) DK0582164T3 (es)
ES (1) ES2125285T3 (es)
FI (1) FI933398A7 (es)
GR (1) GR3029778T3 (es)
HU (1) HUT67460A (es)
IL (1) IL106490A0 (es)
MX (1) MX9304547A (es)
NO (1) NO932694L (es)
PL (1) PL299888A1 (es)
TW (1) TW224096B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646281A (en) 1990-12-28 1997-07-08 Neurogen Corporation Certain 4-piperidino- and piperazinomethyl-2-phenyl imidazole derivatives; dopamine receptor subtype specific ligands
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
JPH10509713A (ja) * 1994-11-23 1998-09-22 グラクソ、ウェルカム、インコーポレーテッド α−１Ｃアドレナリン作動性レセプターのアンタゴニストとしてのオキサゾール誘導体
US5700826A (en) * 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
AU6167696A (en) * 1995-06-07 1996-12-30 Dade Chemistry Systems Inc. Preparation of immunogens and other conjugates of drugs
EP0900081A4 (en) * 1996-04-03 2002-01-09 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
US5866574A (en) * 1997-04-10 1999-02-02 Kyowa Hakko Kogyo Co., Ltd. Pancreatitis remedy
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
PE20000354A1 (es) 1998-04-03 2000-05-20 Advanced Medicine Inc Nuevos compuestos y usos anestesicos locales
US6462034B1 (en) 1998-04-03 2002-10-08 Theravance, Inc. Local anesthetic compounds and uses
US7582680B1 (en) * 1998-11-12 2009-09-01 Purdue Research Foundation Methods and compositions for treating mammalian spinal cord injuries
US7265115B2 (en) 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
DE19924818A1 (de) 1999-05-29 2000-11-30 Bayer Ag Substituierte Phenylcyclohexancarbonsäureamide
DE19924819A1 (de) * 1999-05-29 2000-11-30 Bayer Ag Substituierte Phenylcyclohexancarbonsäurebenzylamid (Adenosinaufnahmeinhibitoren)
JP2003501425A (ja) * 1999-06-03 2003-01-14 イーライ・リリー・アンド・カンパニー １０，１１−メタノジベンゾスベラン誘導体の製造方法
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904738D0 (sv) * 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
DE10044792A1 (de) * 2000-09-11 2002-04-04 Bayer Ag Substituierte Phenylcyclohexancarbonsäureamide und ihre Verwendung
AR030817A1 (es) 2000-10-02 2003-09-03 Novartis Ag Derivados de diazacicloalcanodiona
WO2002076962A1 (en) * 2001-03-23 2002-10-03 Nippon Soda Co.,Ltd. Process for producing 3-oxo-2-(2-thiazolyl)propanenitrile and intermediate
EP1389121B1 (en) * 2001-04-24 2012-02-22 Purdue Research Foundation Method and compositions for treating mammalian nerve tissue injuries
US6649761B2 (en) * 2001-05-30 2003-11-18 Merck & Co., Inc. Process for preparing piperazinepentaneamide HIV protease inhibitors
DE10150310A1 (de) * 2001-10-11 2003-04-24 Bayer Ag Substituierte Piperazincyclohexancarbonsäureamide und ihre Verwendung
CA2487141C (en) * 2002-06-24 2011-08-02 Janssen Pharmaceutica N.V. Process for the production of n-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide
KR100694181B1 (ko) * 2005-11-25 2007-03-12 연세대학교 산학협력단 근원세포 또는 근섬유로부터 신경세포 분화를 유도하는화합물, 이를 포함하는 약학적 조성물, 신경세포 분화를유도하는 방법 및 신경세포 분화를 유도하는 화합물을검색하는 스크리닝 방법
WO2011000945A2 (en) 2009-07-03 2011-01-06 Nensius Research A/S Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns
KR101423176B1 (ko) 2011-11-29 2014-07-25 제일모직 주식회사 포지티브형 감광성 수지 조성물, 이를 사용하여 제조된 감광성 수지막 및 상기 감광성 수지막을 포함하는 반도체 소자
KR101432603B1 (ko) 2011-12-29 2014-08-21 제일모직주식회사 감광성 노볼락 수지, 이를 포함하는 포지티브형 감광성 수지 조성물, 이를 사용하여 제조된 감광성 수지막 및 이를 포함하는 반도체 소자
MX2017005462A (es) 2014-11-05 2017-07-28 Flexus Biosciences Inc Agentes inmunorreguladores.
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
CN109456285A (zh) * 2018-10-29 2019-03-12 安徽省庆云医药股份有限公司 一种雷诺嗪的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL137318C (es) * 1964-06-09
IT1033040B (it) * 1970-02-21 1979-07-10 Serono Ist Farm 4 5 difenilossazoli 2 amminometil e 2,2 amminoetil sostituiti
US4020082A (en) * 1970-02-21 1977-04-26 Enzo Marchetti 2-Aminomethyl- and 2-(2-aminoethyl)-substituted 4,5-diphenyloxazoles
GB1527483A (en) * 1976-02-12 1978-10-04 Mitsubishi Chem Ind 2-aminomethyl-5-phenyloxazoles and the pharmaceutically acceptable acid addition salts thereof
FR2459242A1 (fr) * 1979-06-21 1981-01-09 Delalande Sa Derives du benzimidazole portant en position 1 une chaine aralkyle substituee, leur procede de preparation et leur application en therapeutique
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
NZ223847A (en) * 1987-04-01 1989-12-21 Janssen Pharmaceutica Nv Substituted piperazine derivatives and pharmaceutical compositions
JP2852659B2 (ja) * 1988-03-03 1999-02-03 富山化学工業株式会社 ピペラジン誘導体およびその塩
JP3003148B2 (ja) * 1989-01-05 2000-01-24 藤沢薬品工業株式会社 チアゾール化合物、その製造法およびそれを含有する医薬組成物
EP0388909A3 (en) * 1989-03-22 1991-05-08 Fujisawa Pharmaceutical Co., Ltd. Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
AU643235B2 (en) * 1989-09-15 1993-11-11 Gensia Pharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CA2125964C (en) * 1991-12-18 2001-06-19 Neng-Yang Shih Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine h3 agonists/antagonists

Also Published As

Publication number Publication date
DE69322707D1 (de) 1999-02-04
FI933398A0 (fi) 1993-07-29
NO932694L (no) 1994-02-01
NO932694D0 (no) 1993-07-27
KR940005614A (ko) 1994-03-21
HK1014714A1 (en) 1999-09-30
GR3029778T3 (en) 1999-06-30
AU670953B2 (en) 1996-08-08
FI933398L (fi) 1994-02-01
JP3478852B2 (ja) 2003-12-15
DK0582164T3 (da) 1999-08-23
CA2101311A1 (en) 1994-02-01
PL299888A1 (en) 1994-04-18
IL106490A0 (en) 1993-11-15
JPH06157472A (ja) 1994-06-03
DE69322707T2 (de) 1999-08-19
CN1085216A (zh) 1994-04-13
TW224096B (es) 1994-05-21
ATE174913T1 (de) 1999-01-15
US5382584A (en) 1995-01-17
FI933398A7 (fi) 1994-02-01
HUT67460A (en) 1995-04-28
EP0582164A1 (en) 1994-02-09
EP0582164B1 (en) 1998-12-23
AU4423293A (en) 1994-02-03
MX9304547A (es) 1994-02-28

Similar Documents

Publication Publication Date Title
ES2125285T3 (es) Derivados inhibidores de la reabsorcion de adenosina de difenil-oxazoles, tiazoles e imidazoles.
ES2151897T3 (es) Benzoxazinonas como inhibidores de la transcriptasa inversa de vih.
ES2128552T3 (es) Combinacion de un inhibidor de la biosintesis del colesterol y un inhibidor de la absorcion del colesterol beta-lactama.
ES2116131T3 (es) Derivados de naftaleno, su procedimiento de preparacion y productos intermediarios adecuados, y las composiciones farmaceuticas que los contienen.
EE03681B1 (et) Asendatud imidasoolid, millel on vähivastane ja tsütokiine inhibeeriv toime
CO4290359A1 (es) Metodo para tratar la alopecia androgenica con inhibidores 5-alfa-reductasa
ES2101261T3 (es) Uso de taxol para la fabricacion de un medicamento para el tratamiento del cancer.
ES2128791T3 (es) Derivados espirocetales, composiciones que los contienen y su uso como agentes terapeuticos.
BR9405139A (pt) Derivados do triazol, inseticida e acaricida e processos para produção dos mesmos
ES2180933T3 (es) Inhibidor de la serina-proteasa.
RU94044453A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования себореи и угрей
MX9302459A (es) Derivados imino ciclicos, medicamentos que contienen estos compuestos y procedimientos para su preparacion.
ATE40822T1 (de) Aromatase-hemmende 1,2,3-triazol-1-yl-, tetrazol- 1-yl- und tetrazol-2-yl-verbindungen.
ES2192779T3 (es) Modificacion cristalina de 1-(2,6-difluorbencil)-1h-1,2,3-triazol-4-carboxamida y su uso como antiepileptico.
ES2194933T3 (es) Inhibidores de la agregacion plaquetaria.
ES2114289T3 (es) Aminoalcanimidazoles y -triazoles acilados.
MX9301863A (es) Morfolin y tiomorfolin 4-ilamidas
ES2056789T3 (es) Inhibicion de la ruta de la 5-lipoxigenasa.
MX9306178A (es) Bencimidazoles medicamentos que contienen estos compuestos yprocedimientos para su preparacion.
ES2132503T3 (es) Derivado de diarilheptanoide y composicion farmaceutica que lo contiene.
ES2073922T3 (es) Procedimiento para mejorar la eficacia terapeutica de agentes antifungicos liposolubles de la familia de los imidazoles y composicion para la realizacion de este procedimiento.
ES2127530T3 (es) Inhibicion de las infecciones retrovirales mediante administracion de compuestos del acido naftalenosulfonico.
ES2099841T3 (es) 2'-desoxi-2'-fluorocoformicina y estereoisomeros de la misma.
KR970704441A (ko) 사람 면역결핍증 바이러스 프로테아제 억제제 배합물(HIV Protease inhibitor combination)
AR005136A1 (es) Compuestos antibioticos oligosacaridos hidrosolubles, una composicion farmaceutica que los contienen y el uso de los mismos para la preparacion de un medicamento

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 582164

Country of ref document: ES